---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-025037"
form_type: "8-K"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2026-05-22T20:30:23+00:00"
generated_at: "2026-05-22T20:52:27.140000+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Akari Therapeutics raises ~$5.5M via private placement of ADSs and warrants

## Summary
- Gross proceeds of ~$5.5M from 1,470,588 ADSs at $3.74 per unit; three closings through July 15, 2026.
- Each unit includes one ADS (or pre-funded warrant) plus Series H/I/J warrants exercisable at $3.74 per ADS.
- Warrants require shareholder approval; pre-funded warrants exercisable immediately.
- Net proceeds for working capital and general corporate purposes; Paulson Investment paid 2% cash fee plus 117,647 ADSs.
- Offering exempt from registration under Section 4(a)(2) and Regulation D.

## SEC filing metadata
- accession: 0001493152-26-025037
- form_type: 8-K
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2026-05-22T20:30:23+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000149315226025037/0001493152-26-025037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000149315226025037/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-025037
- JSON: https://secwatch.observer/filing/0001493152-26-025037.json
- Plain text: https://secwatch.observer/filing/0001493152-26-025037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.